ALFAXAN ANAESTHETIC INJECTION

Quốc gia: Úc

Ngôn ngữ: Tiếng Anh

Nguồn: APVMA (Australian Pesticides and Veterinary Medicines Authority)

Thành phần hoạt chất:

ALPHAXALONE

Sẵn có từ:

ZOETIS AUSTRALIA PTY LTD

INN (Tên quốc tế):

alphaxalone(10mg/mL)

Dạng dược phẩm:

PARENTERAL LIQUID/SOLUTION/SUSPENSION

Thành phần:

ALPHAXALONE ANAESTHETIC Active 10.0 mg/ml

Các đơn vị trong gói:

10mL; 20mL; 50mL

Lớp học:

VM - Veterinary Medicine

Nhóm trị liệu:

CAT | DOG | BITCH | CASTRATE | CAT - QUEEN | CAT - TOM | KITTEN | PUPPY

Khu trị liệu:

ANAESTHETICS/ANALGESICS

Chỉ dẫn điều trị:

ANAESTHETIC - LOCAL/GENERAL | GENERAL ANAESTHETIC | IMMOBILISER | LOCAL ANAESTHETIC | PREMEDICATION | SEDATIVE | TRANQUILLISER | TRAVEL SICKNESS

Tóm tắt sản phẩm:

Poison schedule: 4; Withholding period: WHP:N/A; Host/pest details: CAT: [ANAESTHETIC - LOCAL/GENERAL]; DOG: [ANAESTHETIC - LOCAL/GENERAL]; An injectable anaesthetic for dogs and cats.Contraindicated for use in combination with other intravenous anaesthetic agents. See SAFETY section on leaflet also.

Tình trạng ủy quyền:

Registered

Ngày ủy quyền:

2023-07-01

Tờ rơi thông tin

_A_
_LFAXAN_
_®_
ANAESTHETIC INJECTION
_A_
_LFAXAN_
_®_
ANAESTHETIC INJECTION
_A_
_LFAXAN_
_®_
146.25mm
160mm
Overall size 146.25mm x 160mm
is 100% size
APVMA file name: 52881_46610_10mL_primary_MPL_V1.pdf
Dimensions: primary pack = 146.25mm (wide) x 160mm (high)
Scale: 100% on A4
Date: 15 – 12 – 2009
8
9
0
1
2
7
6
5
4
3
12
PMS
186
PMS
281
K
PRESCRIPTION ANIMAL REMEDY
KEEP OUT OF REACH OF CHILDREN
FOR ANIMAL TREATMENT ONLY
PRESCRIPTION ANIMAL REMEDY
KEEP OUT OF REACH OF CHILDREN
FOR ANIMAL TREATMENT ONLY
READ THE ENCLOSED LEAFLET
BEFORE USING THIS PRODUCT
DIRECTIONS FOR USE:
ALFAXAN
® ANAESTHETIC INJECTION
SHOULD NOT BE USED IN COMBINATION
WITH OTHER INTRAVENOUS ANAESTHETIC
AGENTS. IT SHOULD BE GIVEN BY SLOW
CONTINUOUS INJECTION OVER 60 SECONDS
AND NOT AS A RAPID DOSE.
For use by the intravenous route in
dogs and cats, or the intramuscular
route in cats.
DOSE
INDUCTION:
Dogs
Un-premedicated: 3 mg/kg (0.3 mL/kg)
Premedicated:
2 mg/kg (0.2 mL/kg)
Cats
Un-premedicated: 5 mg/kg (0.5 mL/kg)
Premedicated:
5 mg/kg (0.5 mL/kg)
MAINTENANCE: Refer to leaflet.
JUROX Pty. Limited
85 Gardiner Road
Rutherford NSW 2320 Australia
Infoline 1800 023 312
Registered to Jurox New Zealand Limited
Phone [phone]
(P.A.R.) Class II, ACVM No. A8040
Licensed under U.S. and associated patents.
FIRST AID: If poisoning occurs contact
a Doctor or Poisons Information Centre.
Phone Australia 13 11 26
New Zealand 0800 764 766
STORE below 30°C (Room Temperature).
Protect from light.
See leaflet for full instructions.
DISPOSE of empty container by wrapping
with paper and placing in garbage.
APVMA Approval No. 52881/10mL/0809
See base for B and EXP
407496
10 mg/mL ALFAXALONE
AN INJECTABLE
ANAESTHETIC FOR
DOGS AND CATS.
10 ML
10 mg/mL ALFAXALONE
AN INJECTABLE
ANAESTHETIC FOR
DOGS AND CATS.
10 ML
ANAESTHETIC INJECTION
Insert
80% Barcode
10 ML
APPROVED
LABEL
Info
PEST


Verified
r-
)>
a>
rT1
r-
_en _
0
r-
c
-I
0
z
_en _
a>
m
-<
0
z
0
THE
ii
Please
Check
list
Prior
to
Approval
THIS
IS
YOUR
PROOF-
PROOF
READING
ISYOUR
RESPONSIBILITY
-
_rud _

Đặc tính sản phẩm

ALFAXAN ANAESTHETIC INJECTION
Page 1 of 6
ISSUED:
3 FEBRUARY 2016
SAFETY DATA SHEET
SECTION 1: IDENTIFICATION OF CHEMICAL PRODUCT AND COMPANY
PRODUCT NAME:
ALFAXAN ANAESTHETIC INJECTION
PRODUCT CODE:
502135 (10 mL); 503320 (20 mL)
RECOMMENDED USE:
An injectable anaesthetic for dogs and cats.
RESTRICTIONS ON USE:
For animal treatment only.
COMPANY IDENTIFICATION:
Jurox Pty Limited
ADDRESS:
85 Gardiner Street,
Rutherford, NSW 2320,
Australia
EMAIL:
[e-mail]
CUSTOMER CENTRE:
1800 023 312
NATIONAL POISONS INFORMATION CENTRE:
13 1126 (Australia-wide)
EMERGENCY TELEPHONE NUMBER:
1800 023 312 (9am – 5pm, Monday to Friday)
SECTION 2: HAZARDS IDENTIFICATION
This product has been assessed according to GHS and is classified as
non-hazardous.
SIGNAL WORD: None.
GHS PICTOGRAMS: None.
PRECAUTIONARY STATEMENTS: None.
SECTION 3: COMPOSITION / INFORMATION ON INGREDIENTS
INGREDIENT
CAS NO.
CONTENT
Alfaxalone
23930-19-0
1%
Hydroxypropyl-beta-cyclodextrin
128446-35-5
< 10%
Ingredients not contributing to the hazards
to 100%
ALFAXAN ANAESTHETIC INJECTION
Page 2 of 6
SECTION 4: FIRST AID MEASURES
GENERAL INFORMATION: Never give fluids or induce vomiting if a patient
is unconscious or convulsing
regardless of cause of injury. If medical advice/attention is needed,
have this SDS, product container or label
at hand.
SYMPTOMS AND EFFECTS OF EXPOSURE: Sedation, anaesthesia, CNS effects.
INHALATION: If fumes, aerosols or combustion products are inhaled
remove from contaminated area. Other
measures are usually not necessary. If respiratory symptoms occur,
remove patient to fresh air. Lay patient
down and keep warm and rested. If breathing is shallow or has stopped,
ensure airway is clear and apply
resuscitation. If breathing is difficult, give oxygen and seek medical
assistance immediately.
INGESTION: If swallowed do NOT induce vomiting. Give water to rinse
out mouth, then provide liquid slowly
and as much as casualty can comfortably drink. Never give liquid to a
person showing signs of being sleepy
or with reduced awareness; i.e.

Bảng dữ liệu an toàn

WWW.JUROX.COM.AU
Customer Service 1800 023 312
® Registered Trademark of Jurox Pty Ltd
TECHNICAL NOTES
REGISTERED NAME
Alfaxan® Anaesthetic Injection
ACTIVE CONSTITUENTS
Alfaxalone 10 mg/mL
DESCRIPTION
Alfaxan® is a clear, colourless, sterile solution for injection
presented in a multi-use injection vial.
ACTIONS
Alfaxalone (3-α-hydroxy-5-α-pregnane-11,20-dione) is a neuroactive
steroid molecule with properties of a general anaesthetic. The
primary mechanism for the anaesthetic action of alfaxalone is
modulation of neuronal cell membrane chloride ion transport, induced
by binding of alfaxalone to GABA-A cell surface receptors.
PHARMACOKINETIC PARTICULARS
The volume of distribution after a single injection of clinical doses
of Alfaxan® in dogs and cats is 2.4 L/kg and 1.8 L/kg, respectively.
In
cats, the mean terminal plasma elimination half-life (t1/2) for
alfaxalone is approximately 45 minutes for a 5 mg/kg dose. Mean plasma
clearance for a 5 mg/kg dose is 25.1 ± 7.6 mL/kg/min. In dogs, the
mean terminal plasma elimination half-life (t1/2) for alfaxalone is
approximately 25 minutes for a 2 mg/kg dose. Plasma clearance for a 2
mg/kg dose is 59.4 ± 12.9 mL/kg/min. Alfaxalone metabolites
are likely to be eliminated from the dog and cat by the hepatic/faecal
and renal routes, similar to other species.
CONTRAINDICATIONS
Alfaxan® is contraindicated for use in combination with other
intravenous anaesthetic agents.
ALFAXAN
®
Anaesthetic Injection
WWW.JUROX.COM.AU
Customer Service 1800 023 312
® Registered Trademark of Jurox Pty Ltd
TECHNICAL NOTES
PRECAUTIONS
ALFAXAN® SHOULD BE GIVEN BY SLOW CONTINUOUS INJECTION AND NOT AS A
RAPID DOSE. Some patients, especially dogs, may undergo
a short period of apnoea on induction using Alfaxan® by the
intravenous route. This can be avoided by inducing anaesthesia by slow
continuous intravenous injection over 60 seconds, while assessing the
degree of anaesthesia achieved.
Appropriate analgesia should be provided in cases where procedures are
anticipated to be painful.
AS